Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

NCT00937521 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1507

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Meningitis
Meningococcal Infections

Interventions

BIOLOGICAL: Meningococcal B vaccine
BIOLOGICAL: Meningococcal B vaccine
BIOLOGICAL: Meningococcal B vaccine
BIOLOGICAL: Meningococcal B vaccine
BIOLOGICAL: Meningococcal B vaccine
BIOLOGICAL: Meningococcal B vaccine
BIOLOGICAL: Control
BIOLOGICAL: Meningococcal B vaccine with antipyretic

Sponsor

Novartis Vaccines